40607ES08)
In the late-stage study, adults who were overweight or obese and had a weight-related medical problem not including diabetes and took the drug at its highest dose lost an average of 48 pounds compared to the placebo, the company said
Subject of Research Compounded GLP-1 weight-loss medications (semaglutide, tirzepatide) regulation and sourcing by clinics and compounding pharmacies Article Title : (Not provided) News Publication Date : 17-Jul-2026 Web References : References : DOI 10.1001/jamahealthforum.2026.2207 (as given) Image Credits : (Not provided) Keywords : GLP-1, compounded medications, semaglutide, tirzepatide, sterile compounding, FDA enforcement, weight-loss clinics, regulatory oversight, patient safety, JAMA Health Forum Tags: secret shopper research in medical spa practicescompounded weight-loss drugsdemand for semaglutide and tirzepatideFDA enforcement of compounded drugsGLP-1 therapymarketing practices of weight-loss clinicsmedical spas selling compounded medicationsregulation and oversight of compounding pharmaciesregulation of personalized pharmacy formulationssafety concerns of compounded weight-loss drugssourcing of active ingredients in compounded medications
Retatrutide is not currently available as a licensed treatment in the UK and may only be accessed through approved clinical trial settings
Look at the four-week trend rather than reacting to daily weigh-ins
And yes, most patients continue using Ozempic without serious issues
